AVTEAerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 1.70 $ 0.00 (0 %)    

Tuesday, 02-Jul-2024 09:54:11 EDT
QQQ $ 482.06 $ 2.17 (0.45 %)
DIA $ 391.07 $ 0.23 (0.06 %)
SPY $ 545.09 $ 1.35 (0.25 %)
TLT $ 90.67 $ 0.00 (-0.01 %)
GLD $ 215.85 $ 0.58 (0.27 %)
$ 1.7
$ 1.70
$ 1.66 x 5,000
$ 0.00 x 0
$ 1.68 - $ 1.70
$ 1.25 - $ 32.42
1,268,682
na
47.25M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evercore-isi-group-downgrades-aerovate-therapeutics-to-in-line-lowers-price-target-to-2

Evercore ISI Group analyst Liisa Bayko downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Outperform to In-Line and lowers ...

 guggenheim-downgrades-aerovate-therapeutics-to-neutral

Guggenheim analyst Vamil Divan downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

 wells-fargo-downgrades-aerovate-therapeutics-to-equal-weight-lowers-price-target-to-2

Wells Fargo analyst Tiago Fauth downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Overweight to Equal-Weight and lowers th...

 td-cowen-downgrades-aerovate-therapeutics-to-hold

TD Cowen analyst Joseph Thome downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold.

 jefferies-downgrades-aerovate-therapeutics-to-hold-lowers-price-target-to-2

Jefferies analyst Eun Yang downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold and lowers the price target from ...

 btig-downgrades-aerovate-therapeutics-to-neutral

BTIG analyst Julian Harrison downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

 why-is-small-cap-heart-disease-focused-aerovate-therapeutics-stock-plummeting-on-monday

Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hy...

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 aerovate-therapeutics-presents-baseline-data-from-phase-2b-portion-of-impahct-trial-at-ats-2024-international-conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study ...

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 aerovate-therapeutics-q1-2024-gaap-eps-083-misses-074-estimate

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate ...